LEP and obesity due to melanocortin 4 receptor deficiency: Since its discovery in 1994, leptin replacement therapy has been extensively investigated in rodent models as well as in children and adults, where parenteral leptin replacement therapy has been approved for the treatment of congenital leptin deficiency, diabetes, and obesity [8,9].